
As per the bill, a DRA body will be established to address all components of drug manufacturing, sales and distribution.
Furthermore, a Drug Policy Board will also be formed, and will be headed by the national regulations and services secretary.
The DRA will be headed by a chief executive officer (CEO), who will be appointed on merit by the prime minister on recommendation of members of the Drug Policy Board.
The Senate had approved the bill on October 17.
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ